IIVS, Advancing Science & Animal Welfare Together | SOT 2024 Issue
IIVS to Exhibit at ToxExpo 2024
Please visit us at booth #1232 during ToxExpo. We have exciting information to share about new assays, test guidelines and more!

In attendance will be: Amanda Ulrey (President), Kristie Sullivan (VP of Education and Outreach), Hans Raabe (COO), Holger Behrsing (Director of Respiratory Services), Vivek Patel and Allison Hilberer (Study Directors) and Brent Gilbert (Director of Business Development).

Email us at clientservices@iivs.org to arrange a meeting with any members of our team.
IIVS Posters at SOT
Refinement and Optimization of the Photo-KeratinoSens™ Assay to Evaluate Photoallergy Potential

Presenting Author:
Katherine Bouchard
Abstract/Poster Board number:
4220/P769

Session Title:
New Approach Methods: In Vitro II

Session Date and Time:
12 March, 2:15 PM to 4:15 PM
Approaches to Evaluation of Solvents for Use in Photosafety Testing

Presenting Author:
Allison Hilberer
Abstract/Poster Board number:
4238/P787

Session Title:
New Approach Methods: In Vitro II

Session Date and Time:
12 March, 2:15 PM to 4:15 PM
Advancing Flexibility for Defined Approach Guidelines: Developing Performance Standards to Incorporate Alternate Information Sources into the Defined Approach for Skin Sensitization Guideline

Presenting Author:
Kristie Sullivan
Abstract/Poster Board number:
4576/P41

Session Title:
Regulation/Policy

Session Date and Time:
13 March, 2:15 PM to 4:15 PM
Predicting GHS Hazard Classification for Eye Irritation/ Corrosion Potential of Agrochemical Formulations Using Defined Approaches
Abstract/Poster Board number:

Session Title:
Ocular Toxicology

Session Date and Time:
11 March, 11:45 AM to 1:45 PM
IIVS Participation in Continuing Education
AM05: New Approach Methodologies for Primary Dermal Irritation: Implementing Human-relevant Testing Approaches
Hans Raabe, IIVS COO, will take part in a CE course, introducing in vitro and in chemico test methods which have been validated for identifying GHS Category 1 and 2 ocular irritants, and are applicable to classifying substances into EPA categories I and II. The presentation will consist of highlighting multiple assays which have been developed and validated for international regulatory purposes. The course also includes a discussion of current applicability and limitations of these methods and how they can be used to support categorization and labeling requirements and coverage of other test methods under development which may be able to discriminate between mild and moderate irritation categories.
PM13: Human-Derived In Vitro and Ex Vivo Test Systems to Assess Respiratory Toxicity of Chemicals
Holger Behrsing, Director of Respiratory Services, will present an an overview of in vitro and ex vivo pulmonary models and discuss the advantages and challenges in their incorporation into screening and testing strategies. Holger will cover both 2-D models as screening tools as well as 3-D organotypic models of the airway tract including Reconstructed human airway tissues, humna-donor derived spheroids and organoids. There will also be time devoted to a presentation on the utility of Precision-Cut human Lung Slices (PCLS) to model traditional endpoints such as cytotoxicity as well as chronic-exposure related adverse outcomes (e.g. persistent inflammation, goblet cell hyperplasia) and functional outcomes (modulation of ciliary beat frequency) which may reflect serious health complications that can lead to various disease states.
PM12: Bridging the Gap: Educational Needs and Resources
Kristie Sullivan, VP of Education and Outreach will focus on outlining the state of the science of computational approaches for exposure, bioactivity, weight-of-evidence, and IVIVE assessments within an NGRA evaluation for safety assessment. She will also discuss the educational and training needs and resources to improve uptake and acceptance of these tools and lead a discussion with the audience about how we can move towards more widespread adoption.
Workshops & Informational Sessions
11 March, 1:45 PM to 4:30 PM
Kristie Sullivan, VP of Education and Outreach will Co-chair and introduce “Allergies Are More Than Skin Deep: Establishing Regulatory Test Methods for Respiratory Sensitization”. This session will update attendees on the latest progress in exploring assessment approaches to identify respiratory sensitizing materials, and evaluate and implement promising approaches to meet international regulatory needs.
11 March, 5:00 PM to 7:00 PM

Hans will co-present with Toxys CEO Giel Hendricks on "In Vitro Assays for Genetic Toxicity, Developmental Toxicity, and Mechanistic Toxicity". He will specifically discuss the transferability of the ToxTracker assay and availability in the US. Also included in this session will be case studies from scientists who have implemented ToxTracker and other assays developed by Toxys at their own facilities.
13 March, 11:00 AM to 12:20 PM
Kristie Sullivan, VP of Education and Outreach will present during “The Modernization of the Cosmetic Regulation Act: Perspectives on Recent Implementation Activities and Confirming Safety in Cosmetic Products”. This sessions features presentations and a panel discussion from FDA, industry, consultant, and non-profit experts to share the latest updates on MoCRA implementation. Kristie's presentation, The Future of NAMs in Informing Safety for Cosmetic Ingredients and Products, will discuss how nonanimal methods can fulfill safety assessment needs for companies and FDA under MoCRA.
Interested in Networking?
The In Vitro and Alternative Methods specialty section SOT reception will take place on Tuesday evening between 6:00 and 7:30 PM at the Hyatt Regency, Salt Lake Ballroom C.

All are welcome to attend!
We want to hear from you
IIVS is always interested in the needs and requests from researchers interested in advancing the awareness, acceptance and use of alternative methods. If you have any input on methodologies of interest, please don't hesitate to contact us at clientservices@iivs.org.
Connect With Us